- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07697742
Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE) (ELIMINATE)
Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE): A Prospective Observational Surgical Cohort Study of Feasibility, Safety, and Radiographic Outcomes
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The primary objective of ELIMINATE, a prospective, single-centre, observational surgical cohort study, is to determine whether a standardized microsurgical procedure to evacuate spontaneous lobar intracranial hemorrhage (ICH) is feasible, safe and surgically efficacious in achieving a postoperative residual ICH volume <15cc on 24-hour postoperative CT imaging. The secondary objectives include assessment of tool-tissue forces and bleeding, residual ICH volume postoperatively, and determining the recruitment rate for patients with spontaneous lobar ICH.
The primary clinical outcome will be the proportion of enrolled patients achieving residual ICH volume <15cc on postoperative CT scan at 24 hours. Key outcomes are:
Radiographic: percent evacuation; residual volume (continuous + dichotomized). Functional: mRS at 6 months; EQ-5D-5L at 6 months; mortality at 30 and 180 days.
Intraoperative: force metrics; bleeding quantification; operative time; blood loss.
Feasibility: recruitment rate; proportion operated ≤16 hours; completeness of imaging.
Safety: symptomatic rebleeding ≤72h; postoperative deficits; infections; unplanned OR return; 30-day mortality.
A maximum of 27 adult patients will be enrolled.
Inclusion criteria:
- Adults > 18 years
- CT evidence of acute, spontaneous lobar ICH defined as located <1cm from the cortical surface
- ICH volume is >30cc but <80cc as measured by (length x width x height)/2
- GCS 5-14 at presentation
- NIHSS >5
- Surgery deemed to be feasible within 16h of symptom onset
Exclusion criteria:
- Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely)
- Intraventricular extension estimated to involve >50% of the lateral ventricle
- Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS>1 at baseline)
- Individuals presenting with GCS <5 at presentation
- Primary basal ganglia hemorrhage with lobar extension
- End-stage organ failure or life expectancy <6 months
- For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.
This study consists of one 180-day study period for each subject. Subjects will be hospitalized for care after their lobar ICH and surgical intervention according to the current standard of care. Subjects will undergo phone assessment on Day 180 by a trained assessor.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Michael D HILL, MD
- Numer telefonu: 403-210-7786
- E-mail: michael.hill@ucalgary.ca
Lokalizacje studiów
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 2T9
- Foothills Medical Centre
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
• Adults > 18 years
- CT evidence of acute, spontaneous lobar ICH defined as located <1cm from the cortical surface
- ICH volume is >30cc but <80cc as measured by (length x width x height)/2
- GCS 5-14 at presentation
- NIHSS >5
- Surgery deemed to be feasible within 16h of symptom onset
Exclusion Criteria:
• Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely)
- Intraventricular extension estimated to involve >50% of the lateral ventricle
- Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS>1 at baseline)
- Individuals presenting with GCS <5 at presentation
- Primary basal ganglia hemorrhage with lobar extension
- End-stage organ failure or life expectancy <6 months
- For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Single cohort deisgn
Surgical evacuation of ICH using microsurgical technicque.
|
Microsurgical hematoma evacuation using microscope and neuronavigation
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Recruitment rate
Ramy czasowe: Quarterly from study onset through study completion with the final recruitment rate recorded at the end of study; total time 12 months
|
Total recruitment will be recorded each month and report as number of patients recruited per calendar month as an average for duration of the study.
The numerator will be the cumulative total number of pateints recruitment and the denominator will be the number of months elapsed since study start.
The demoninator can be a fractional number; the numerator will also be a positive integer.
|
Quarterly from study onset through study completion with the final recruitment rate recorded at the end of study; total time 12 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Residual hematoma volume
Ramy czasowe: Up to 2 days after enrolment; post-operative core lab assessment of the 18-54 hour follow-up CT brain scan. The Core Lab will measure residual hematoma volume using summative planimetry over the volume of each CT scan slice image.
|
Residual hematoma volume
|
Up to 2 days after enrolment; post-operative core lab assessment of the 18-54 hour follow-up CT brain scan. The Core Lab will measure residual hematoma volume using summative planimetry over the volume of each CT scan slice image.
|
|
modified Rankin Scale Score
Ramy czasowe: at 90 days and 180 days after enrolment.
|
mRS score is an integer scale ranging from 0 to 6 (7 point interval scale).
Lower score are better and the highest score (6) implies death
|
at 90 days and 180 days after enrolment.
|
|
EuroQoL
Ramy czasowe: at 90 days and 180 days after randomization
|
EQ5D-5L is a 5 domain scale, with a 5 point Likert scale for the quesiton in each domain.
It addresses quality of life and the final score (the EQ5D Index) is adjusted by country to local norms using standardized methodology.
Higher index scores inply a higher quality of life.
|
at 90 days and 180 days after randomization
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Forceps forces
Ramy czasowe: Perioperative/peri-procedural
|
Intra-operative forceps forces during microsurgery.
These devices have haptic measurement capability and will reocrd the degree of force each time dissection or cautery are used.
Recording will be conducted during the entire operative procedure.
|
Perioperative/peri-procedural
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- ELIMINATE 4.0
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Ramy czasowe udostępniania IPD
Kryteria dostępu do udostępniania IPD
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
- ANALITYCZNY_KOD
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .